These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 28065411)

  • 41. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
    Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
    Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values.
    Cserni G; Vörös A; Liepniece-Karele I; Bianchi S; Vezzosi V; Grabau D; Sapino A; Castellano I; Regitnig P; Foschini MP; Zolota V; Varga Z; Figueiredo P; Decker T; Focke C; Kulka J; Kaya H; Reiner-Concin A; Amendoeira I; Callagy G; Caffrey E; Wesseling J; Wells C
    Breast; 2014 Jun; 23(3):259-63. PubMed ID: 24613255
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pathological examination of breast cancer biomarkers: current status in Japan.
    Masuda S
    Breast Cancer; 2016 Jul; 23(4):546-51. PubMed ID: 25239167
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma.
    Faratian D; Munro A; Twelves C; Bartlett JM
    Histopathology; 2009 Jan; 54(2):254-7. PubMed ID: 19207951
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial.
    Ellis MJ; Miller WR; Tao Y; Evans DB; Chaudri Ross HA; Miki Y; Suzuki T; Sasano H
    Breast Cancer Res Treat; 2009 Jul; 116(2):371-8. PubMed ID: 18941892
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma.
    Laurinavicius A; Green AR; Laurinaviciene A; Smailyte G; Ostapenko V; Meskauskas R; Ellis IO
    Oncotarget; 2015 Dec; 6(38):41134-45. PubMed ID: 26512778
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of the international Ki67 working group cut point recommendations for early breast cancer: comparison with 21-gene assay results in a large integrated health care system.
    Shim VC; Baker RJ; Jing W; Puentes R; Agersborg SS; Lee TK; GoreaI W; Achacoso N; Lee C; Villasenor M; Lin A; Kapali M; Habel LA
    Breast Cancer Res Treat; 2024 Jan; 203(2):281-289. PubMed ID: 37847456
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy.
    Synnestvedt M; Borgen E; Russnes HG; Kumar NT; Schlichting E; Giercksky KE; Kåresen R; Nesland JM; Naume B
    Acta Oncol; 2013 Jan; 52(1):91-101. PubMed ID: 22934555
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
    Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
    Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
    Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
    Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer.
    Callari M; Cappelletti V; D'Aiuto F; Musella V; Lembo A; Petel F; Karn T; Iwamoto T; Provero P; Daidone MG; Gianni L; Bianchini G
    Clin Cancer Res; 2016 Jan; 22(2):337-45. PubMed ID: 26423797
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration.
    Leung SCY; Nielsen TO; Zabaglo LA; Arun I; Badve SS; Bane AL; Bartlett JMS; Borgquist S; Chang MC; Dodson A; Ehinger A; Fineberg S; Focke CM; Gao D; Gown AM; Gutierrez C; Hugh JC; Kos Z; Laenkholm AV; Mastropasqua MG; Moriya T; Nofech-Mozes S; Osborne CK; Penault-Llorca FM; Piper T; Sakatani T; Salgado R; Starczynski J; Sugie T; van der Vegt B; Viale G; Hayes DF; McShane LM; Dowsett M;
    Histopathology; 2019 Aug; 75(2):225-235. PubMed ID: 31017314
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.
    Toi M; Saji S; Masuda N; Kuroi K; Sato N; Takei H; Yamamoto Y; Ohno S; Yamashita H; Hisamatsu K; Aogi K; Iwata H; Takada M; Ueno T; Saji S; Chanplakorn N; Suzuki T; Sasano H
    Cancer Sci; 2011 Apr; 102(4):858-65. PubMed ID: 21231986
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer.
    Gudlaugsson E; Skaland I; Janssen EA; Smaaland R; Shao Z; Malpica A; Voorhorst F; Baak JP
    Histopathology; 2012 Dec; 61(6):1134-44. PubMed ID: 22963617
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ki67 Heterogeneity in Estrogen Receptor-Positive Breast Cancers: Which Tumor Type Has the Most Heterogeneity?
    Himuro T; Horimoto Y; Arakawa A; Tanabe M; Saito M
    Int J Surg Pathol; 2016 Apr; 24(2):103-7. PubMed ID: 26353854
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies.
    Romero Q; Bendahl PO; Klintman M; Loman N; Ingvar C; Rydén L; Rose C; Grabau D; Borgquist S
    BMC Cancer; 2011 Aug; 11():341. PubMed ID: 21819622
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
    Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
    J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An inter-observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish breast cancer cooperative group (DBCG).
    Laenkholm AV; Grabau D; Møller Talman ML; Balslev E; Bak Jylling AM; Tabor TP; Johansen M; Brügmann A; Lelkaitis G; Di Caterino T; Mygind H; Poulsen T; Mertz H; Søndergaard G; Bruun Rasmussen B
    Acta Oncol; 2018 Jan; 57(1):83-89. PubMed ID: 29202622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.